Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions
Heart FailureAcute Decompensated Heart Failure
Interventions
DEVICE

Impella BTR

Subjects will be prepared for pump insertion procedure according to clinical site standard of care. Procedural preparations for insertion of the Impella BTR are identical to the insertion of the Impella 5.0/5.5 via the axillary artery. The Impella BTR remains in situ until the patient is sufficiently recovered for removal or is transitioned to another form of support. It is expected that the Impella BTR is in situ for a maximum of 28 days.

Trial Locations (6)

30322

Emory University Hospital, Atlanta

44195

Cleveland Clinic, Cleveland

60208

Northwestern University, Evanston

02111

Tufts Medical Center, Boston

02114

Massachusetts General Hospital, Boston

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abiomed Inc.

INDUSTRY